Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a leading commercial-stage biotechnology company focused on enhancing patient care through the development and commercialization of innovative therapeutic solutions. Specializing in the use of its proprietary Biochronomer™ polymer-based drug delivery platform, Heron is revolutionizing the pharmaceutical landscape by converting daily injectable drugs into weekly or bi-weekly regimens.
The company's product portfolio includes APONVIE, SUSTOL, ZYNRELEF, and CINVANTI, which target unmet medical needs in both acute care and oncology settings. APONVIE is effective in preventing postoperative nausea and vomiting, offering a quick 30-second IV push that is bioequivalent to oral aprepitant. SUSTOL utilizes Heron's Biochronomer® technology to extend therapeutic levels of granisetron for over five days, aiding in the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam, is notably the first extended-release local anesthetic demonstrating superior pain management and reducing opioid use for up to 72 hours post-surgery. Originally approved by the FDA in May 2021, its indication was expanded in January 2024 to cover various soft tissue and orthopedic surgeries. Recently, Heron submitted a Prior Approval Supplement (PAS) for a Vial Access Needle to streamline ZYNRELEF's preparation process, potentially enhancing its adoption in clinical settings.
CINVANTI, an IV formulation of aprepitant, significantly reduces both acute and delayed phases of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, improving overall patient quality of life during treatment.
Financially, Heron Therapeutics is on a robust trajectory, having implemented a cost reduction program projected to save approximately $75 million through 2025. The company has secured $30 million in equity financing and a $50 million working capital facility, aiming to achieve profitability with its current operational strategies.
Heron’s strong focus on clinical excellence and strategic partnerships, such as its recent collaboration with CrossLink Life Sciences to expand ZYNRELEF's sales network, underscores its commitment to delivering substantial value and improving patient outcomes. For more detailed information, visit herontx.com.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
What products does Heron Therapeutics offer?
What is ZYNRELEF used for?
What recent financial initiatives has Heron Therapeutics undertaken?
What is the Biochronomer™ platform?
What are the recent corporate updates from Heron Therapeutics?
When was ZYNRELEF first approved by the FDA?
What is APONVIE used for?
What steps has Heron taken to achieve profitability?
How does SUSTOL help cancer patients?
Where can I find more information about Heron Therapeutics?
